FDA Grants Orphan Drug Designation to Onvansertib for Chronic Myelomonocytic Leukemia
Cardiff Oncology announced on October 21, 2026, that the U.S. Food and Drug Administration has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). Onvansertib is a highly specific, oral inhibitor of polo-like kinase 1 (PLK1) currently under evaluation across multiple tumor types, including a Phase 1 investigator-initiated […]